TY  - JOUR

T1  - Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/108856

UR  - http://doi.org/10.1007/s40273-016-0457-1

PY  - 2016/10/22

AU  - Kearns B

AU  - Pandor A

AU  - Stevenson M

AU  - Hamilton J

AU  - Chambers D

AU  - Clowes M

AU  - Graham J

AU  - Kumar MS

ED  - 

DO  - DOI: 10.1007/s40273-016-0457-1

PB  - Springer Verlag

Y2  - 2025/10/31

ER  -